Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Q3 2025 value amounting to $364.0 million.

  • Rhythm Pharmaceuticals' Short-term Investments rose 4508.53% to $364.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $364.0 million, marking a year-over-year increase of 4508.53%. This contributed to the annual value of $231.4 million for FY2024, which is 725.93% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Short-term Investments stood at $364.0 million for Q3 2025, which was up 4508.53% from $155.4 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Short-term Investments' 5-year high stood at $364.0 million during Q3 2025, with a 5-year trough of $122.4 million in Q2 2022.
  • In the last 5 years, Rhythm Pharmaceuticals' Short-term Investments had a median value of $208.4 million in 2025 and averaged $212.1 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Short-term Investments crashed by 5904.19% in 2022 and then surged by 4508.53% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Short-term Investments (Quarter) stood at $235.6 million in 2021, then fell by 12.73% to $205.6 million in 2022, then grew by 4.94% to $215.8 million in 2023, then rose by 7.26% to $231.4 million in 2024, then surged by 57.27% to $364.0 million in 2025.
  • Its last three reported values are $364.0 million in Q3 2025, $155.4 million for Q2 2025, and $208.4 million during Q1 2025.